B. Braun Launches First FDA-Approved Room-Temperature-Stable Rocuronium Bromide Prefilled Syringe
核心洞察
B. Braun Medical Inc. announced the launch of Rocuronium Bromide Injection, the first and only FDA-approved room-temperature-stable prefilled syringe formulation.
The 50 mg/5 mL preservative-free injection eliminates refrigeration requirements and offers a 24-month shelf life for improved storage flexibility.
The room-temperature stability simplifies pharmacy handling, supports smoother distribution, and helps preserve limited refrigerated space for other medications.
B. Braun Medical Inc. has launched Rocuronium Bromide Injection, marking a significant advancement in neuromuscular blocking agent delivery with the first and only FDA-approved room-temperature-stable prefilled syringe formulation. The product is supplied as a 50 mg/5 mL (10 mg/mL) single-dose Luer lock syringe in a preservative-free, sterile solution.
Storage and Operational Benefits
The room-temperature stability represents a major operational improvement for healthcare facilities. Unlike traditional rocuronium formulations that require refrigeration, B. Braun (搜索)'s injection can be stored at room temperature with a 24-month shelf life, eliminating the need for temperature-controlled transport and refrigerated storage.
This innovation addresses critical pharmacy workflow challenges by simplifying handling procedures and supporting smoother distribution processes. The room-temperature stability also helps preserve limited refrigerated space for other medications that require cold storage, optimizing pharmacy inventory management.
Clinical Impact and Design Features
According to Jeremy Greene, Senior Director of Marketing for IV Fluids and Pharmaceutical Injectables at B. Braun (搜索), the product was "thoughtfully designed to help reduce preparation steps, simplify storage and support clinicians in fast-paced clinical environments—without compromising safety."
The prefilled syringe format eliminates multiple preparation steps typically required with vial-based formulations, potentially reducing medication errors and improving workflow efficiency in operating rooms and critical care settings where rocuronium is commonly used for neuromuscular blockade (搜索).
Portfolio Expansion
The launch reinforces B. Braun (搜索)'s position in the injectable medications market and expands the company's portfolio of essential pharmaceutical products. B. Braun Medical Inc., headquartered in Bethlehem, Pennsylvania, operates as part of the broader B. Braun Group, which employs more than 64,000 people across 64 countries globally.
The company's North American operations include over 30 locations and 8,500 employees, encompassing B. Braun (搜索) Interventional Systems, Aesculap, and CAPS divisions. This product launch aligns with B. Braun's mission to deliver practical, high-quality offerings that support safe and efficient patient care while advancing healthcare safety, reliability, and operational efficiency.